|Systematic (IUPAC) name|
|Molar mass||349.426 g/mol|
|(what is this?)|
MDA-19 is a drug that acts as a potent and selective agonist for the cannabinoid receptor CB2, with reasonable selectivity over the psychoactive CB1 receptor, though with some variation between species. In animal studies it was effective for the treatment of neuropathic pain, but failed to produce cannabis-like behavioural effects.
- Diaz, Philippe; Xu, Jijun (2008). "Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the Treatment of Neuropathic Pain". J. Med. Chem. (American Chemical Society) 51 (16): 4932–4947. doi:10.1021/jm8002203. PMID 18666769.
- Xu, JJ; et al. (Jul 2010). "Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain". Anesthesia and Analgesia 111 (1): 99–109. doi:10.1213/ANE.0b013e3181e0cdaf. PMC 3253719. PMID 20522703.
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|